Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon

Yusuke Kawai, Kenichi Hisamatsu, Hiromi Matsubara, Kazuhiro Dan, Satoshi Akagi, Katsumasa Miyaji, Mitsuru Munemasa, Yoshihisa Fujimoto, Kengo F. Kusano, Tohru Ohe

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Abstract

Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.

Original languageEnglish
Pages (from-to)765-772
Number of pages8
JournalEuropean Heart Journal
Volume30
Issue number7
DOIs
Publication statusPublished - Apr 2009
Externally publishedYes

Keywords

  • Acute coronary syndrome
  • Nicorandil
  • Percutaneous coronary intervention
  • Slow coronary flow phenomenon

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon'. Together they form a unique fingerprint.

Cite this